Developing the Next-Generation Cancer Therapies
Rexahn Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel, targeted therapeutics for the treatment of cancer. Our mission is to extend and improve the lives of cancer patients by developing next-generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects normally associated with cancer treatment.
The Rexahn Approach
Rexahn is focused on discovering and developing new treatments that have the potential to improve the clinical outcome in cancers that are difficult to treat. Through targeting cancer therapies to tumor cells, we aim to minimize effects on healthy tissue and improve safety and quality of life relative to other treatment options.
We believe that optimum anticancer efficacy will be achieved through using combinations of drugs that work in different ways to kill cancer cells and inhibit tumor growth. Rexahn's targeted therapies act synergistically with other anticancer agents and with immunotherapy in preclinical models. We are currently evaluating the combination approach in our clinical studies.